OBJECTIVE:
To compare placebo responses in neuropathic pain syndromes.
CONCLUSIONS:
Placebo response is influenced by the pain syndrome evaluated. These differences should be considered when evaluating novel compounds for the treatment of neuropathic pain conditions.